Aytu BioPharma COO resigns; company winding down manufacturing, suspending R&D

AYTU BIOPHARMA, INC

COO Christopher Brooke resigned effective Oct 13, 2023, to join a development-stage biotech.
Company will not replace COO due to wind down of manufacturing at Grand Prairie, TX facility.
All pipeline research and development programs are indefinitely suspended.
Resignation not due to any disagreement with company or auditors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Brooke

Chief Operating Officer

AYTU · AYTU BIOPHARMA, INC

Effective: 2023-10-13
Filed: October 6, 2023, 7:59 PM ET

On October 3, 2023, Christopher Brooke resigned as Chief Operating Officer of Aytu BioPharma, Inc. (the “Company”), effective October 13, 2023, to pursue another opportunity at a development-stage biotechnology company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Brooke resigned as Chief Operating Officer at AYTU BIOPHARMA, INC.

Action: resigned
Role: Chief Operating Officer

Exact text from the filing

On October 3, 2023, Christopher Brooke resigned as Chief Operating Officer of Aytu BioPharma, Inc. (the “Company”), effective October 13, 2023, to pursue another opportunity at a development-stage biotechnology company.

View on SEC.gov

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-016284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.